BIONTECH SE : Shareholders Board Members Managers and Company Profile ... BioNTech SE (BNTX) Stock Major Holders - Yahoo Finance Shares of Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) are up about 80% and 100% . The top shareholders of Pfizer are Frank A. D'amelio, John Douglas Young, Mikael Dolsten, Vanguard Group Inc., BlackRock Inc. ( BLK ), and State Street Corp. ( STT ). This is in line with BioNTech's capital allocation strategy and the company's commitment to delivering shareholder value," said Helmut Jeggle, Chairman of the Supervisory Board of BioNTech . BioNTech is funded by 16 investors. 30, 2021, 06:20 AM. BioNTech Shareholders Equity (Annual) | BNTX 3 Reasons Shareholders of Moderna and BioNTech May Be In for a Shock And over the last 12 months BNTX stock is up over 168%. Voting Results from BioNTech's Annual General Meeting 2022 Rain of money for BioNTech shareholders: What are Nordex and Meta ... Amid the flurry of executive stock sales in 2020, when shares of companies benefiting from the pandemic skyrocketed, one man stood firm. MAINZ, GERMANY, June 1, 2022 (GLOBE NEWSWIRE) — At the Annual General Meeting ("AGM") of BioNTech SE (Nasdaq: BNTX, "BioNTech" or the "Company") held today, June 1, 2022 . Mutual Fund Ownership. BIONTECH SE : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: BNTX | Nasdaq Fosun Pharma stock surges after German partner BioNTech's clinical success What Kind Of Shareholders Hold The Majority In BioNTech SE's (NASDAQ ... Skip to main content. In addition, analysts at Goldman Sachs have commented positively on the German biotech champion. BioNTech shareholders are in for a windfall. Share issuance costs amounted to P2,000. After such a roaring success, BioNTech is planning to repurchase all its shares and introduce a special cash dividend of €2 a . These Are The Billionaire Investors Behind German Drugmakers Developing ... Funding. Both Sahin and Tureci are the children of Turkish immigrants. 3 reasons to buy BioNTech, and 1 reason to sell BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and ...
